12:00 AM
Dec 09, 2013
 |  BC Week In Review  |  Clinical News  |  Regulatory

Imnovid pomalidomide regulatory update

Germany's Institute for Quality and Efficiency in Healthcare (IQWiG) said Orphan drug Imnovid pomalidomide for multiple myeloma (MM) may cost the German statutory health insurance funds (GKV) up to €57.6 million ($78 million) per year based on a maximum estimate of 3,907 patients at a cost per patient per year of €147,525 ($199,558). Under drug pricing law AMNOG, the additional benefit...

Read the full 282 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >